[Proglumetacin: a simple and practical anti-inflammatory agent for the treatment of hospitalized orthopedic patients].
Forty-six in-patients with osteoarticular and tendon inflammatory, traumatic, degenerative and neoplastic diseases were treated with 600 mg/day of proglumetacin for variable periods ranging between 16 and 60 days. Therapeutic efficacy was considerable, with a significant improvement of all symptoms, regardless of the disease condition the patients were suffering from. Tolerance resulted more than satisfactory, as in no case it was rated less than "good".
D000293:Adolescent; D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D002062:Bursitis / Q000188:drug therapy; D002648:Child; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D013585:Synovitis / Q000188:drug therapy; D052256:Tendinopathy / Q000188:drug therapy; D013997:Time Factors
D007210:Indoleacetic Acids; C019541:proglumetacin
Proglumetacina: antiinfiammatorio semplice e pratico per la terapia dei pazienti ortopedici ospedalizzati.